EUVIMEDDescubrir EUVIMED
CrossrefTarjeta informativa

Empagliflozin effects on cyclophosphamide-induced neurotoxicity in rats without diabetes

ŞERİFE EZGİ DOĞAN, ŞERİFE MEHLİKA KUŞKONMAZ, PINAR CELEPLİ, MEHMET ŞENES, SEMA HÜCÜMENOĞLU, CAVİT ÇULHA

Turkish Journal of Medical Sciences · 2025-02-18 · 55 (1) · 65-71

DOI: 10.55730/1300-0144.5943 ↗
ResumenDatos bibliográficos

Resumen

Background/aim: The objective of this study is to evaluate the effect of empagliflozin on cyclophosphamide-induced neurotoxicity in rats.Materials and methods: A total of 32 male Wistar rats were separated into 4 groups as 8 rats each: control group, cyclophosphamide group, empagliflozin group and the cyclophosphamide plus empagliflozin group. At the end of the experiment rats' brains were removed for biochemical analysis of oxidative stress parameters (malondialdehyde, total sulfhydryl, total oxidant status and total antioxidant capacity) and histopathological analysis.Results: Total sulfhydryl levels were increased in group empagliflozin and group empagliflozin and cyclophosphamide compared to the cyclophosphamide group but did not improve histopathological findings. Furthermore, when empagliflozin treatment was used coupled with cyclophosphamide, necrosis was significantly higher. Conclusion: In conclusion, empagliflozin has no protective effect on cyclophosphamide neurotoxicity in addition it may have neurotoxic effects. Clarification of possible neurotoxic/neuroprotective effects of empagliflozin would be beneficial for diabetic cancer patients who are receiving cyclophosphamide chemotherapy and empagliflozin together.

Conocimiento que se adapta a su trabajo.

Desde un inicio gratuito y la búsqueda bibliográfica personal hasta la Research Suite completa.

Ver tarifas →

¿Se incluyen todos los textos completos editoriales?

No. Registros, resúmenes y textos completos son contenidos diferentes. La disponibilidad depende de la fuente, del acceso abierto y de sus licencias. Un plan EUVIMED no sustituye derechos editoriales adicionales.

Ver tarifas →